Patent ID: 6734175
Filing Date: 2004-05-11
Classification: A46B,A61K,A61P,G01N

Abstract:
A method of treating sexual dysfunction, diabetes, insulin resistance, hyperinsulinemia, Syndrome X, adrenal dysfunction, hypertension, hypercholesterolemia, atherosclerosis, hyperlipoproteinemia, hypertriglyceridemia, or substance abuse, the method comprising the step of administering to a patient, a therapeutically effective amount of a compound that attenuates the binding of agouti-related protein to melanocortin receptors, but does not attenuate the binding of &agr;-melanocyte stimulating hormone to melanocortin receptors in combination with a compound that is a melanocortin receptor agonist, wherin said compound that attenuates the binding of agouti-related protein to melanocortin receptors, but does not attenuate the binding of &agr;-melanocyte stimulating hormone to melanocortin receptors is 8,16-bis-(4-nitro-phenyl) -5,6,8,8a,13,14,16,16a-octahydro-[1,2,4,5,]tetrazino[6,1-aâ€²]diisoquinoline.